News details

SciEx 2019 to Feature New Scientific Discoveries and Advances in Probiotics

­­­

­­­

Montreal, Canada (February 20, 2019) The Rosell® Institute for Microbiome and Probiotics, Lallemand Health Solutions’ integrated research unit, is proud to be the host and sponsor of SciEx, a two-day scientific symposium taking place 26-27 February 2019 in Montreal, Canada. SciEx is an exclusive by invitation only networking and scientific research conference that welcomes prominent researchers and key opinion leaders in the fields of microbiome and probiotics. The goal of SciEx is to bring together like-minded stakeholders who perform research with Lallemand probiotic strains or combination of strains to openly exchange thoughts, knowledge and research findings over a wide range of probiotic topics that include health conditions, methodology, and innovation. Symposium activities include presentations, poster sessions, and networking opportunities.

Dr. Thomas Tompkins, Research Director for Lallemand Health Solutions, said “2019 is a special year for us at the Rosell® Institute as we are celebrating our 85th anniversary. We are as well, proud to host our 10th edition of SciEx, which continues to build support among leading investigators in the field of probiotics. Their ongoing support allows us the opportunity to reaffirm the Rosell® Institute’s commitment to its vision and values – a dynamic scientific approach, an endless quest for innovation, and a deep-rooted belief in the valuable role that probiotics can play in improving human health.”

This year’s speakers and their topics include:

Probiotics and obesity management – Dr. Angelo Tremblay, Université de Laval

Impact of a specific Lactobacillus rhamnosus strain on weight control and body composition in overweight and obese individuals: A randomized clinical trial – Brunella Gonzalez C., Amanda Piano, and Jérémie Auger, Lallemand Health Solutions

PRObiotics for vascular inflammation in MetabolIc SyndromE (PROMISE) – Dr. Anil Nigam, Montreal Heart Institute

A randomized, double-blind trial of a specific Bifidobacterium lactis strain on gastrointestinal outcomes in adults with Prader-Willi syndrome – Dr. Wendy Dahl, University of Florida

Fecal microRNA as biomarkers of intestinal homeostasis and probiotic administration – Dr. Elena Comelli, University of Toronto

Improving Ulcerative Colitis symptoms with probiotics – Systematic review and meta-analysis within a defined population – Ghania Sohail, Western University

Measuring health outcomes in healthy people and the challenges it can pose in clinical trials

Dr. Bobbi Langkamp-Henken, University of Florida

POWER: How to get the most bang for your buck – Dr. Mary Christman, University of Florida

Investigating the interaction between Candida albicans, Lactobacillus sp., and the host-immune response – Dr. Amanda Veri, University of Toronto

Effect of three probiotic strains on safety, tolerance, gut microbial, and immunological composition of infants aged 3 to 12 months – Dr. Esther Jimenez Quintana, Probiosearch, S.L.U.

Depression, past, present, and future – Dr. Roumen Milev, Queen’s University

Funding opportunities through partnership with Mitacs/Genome Canada – Dr. Juliana Muñoz, Génome Québec & Mitacs, Diane Bouchard, Génome Québec, Dr. Dennis McCormac

Current Clinical and Pre-clinical Activities at Lallemand Health Solutions – Chad MacPherson, and Mariana Sandoval

###

About Lallemand

Lallemand Inc. is a privately owned Canadian company specialising in the development, production and marketing of yeast, bacteria, and other ingredients linked to these microorganisms or their industries.

Lallemand Health Solutions

Backed by 85 years of science and expertise in probiotic research and development, Lallemand Health Solutions offers a full line of over 500 ready-to-market probiotic formulas and can help their partners design their own custom formulations using Harmonium, Lafti® or Rosell® probiotic strains and our proprietary protective technologies. Lallemand Health Solutions controls the manufacturing process of its products from lab to the shelf, to ensure customers receive the highest quality probiotic formulation. As a vertically integrated manufacturer, we guarantee our partners receive the full support they need to develop, register, and market their products, making Lallemand Health Solutions a complete probiotic solutions provider.

Lallemand Health Solutions covers more than 60 countries across five continents and is ready to service your probiotic needs. For more information, please visit www.lallemand-health-solutions.com, or contact healthsolutions@lallemand.com

Contact                                                                            

Bérengère Feuz
Marketing Director
Email: healthsolutions@lallemand.com